These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 38558735)

  • 21. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
    Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
    J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards personalized treatment for early stage HER2-positive breast cancer.
    Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
    Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer.
    Lim DW; Greene BD; Look Hong NJ
    Ann Surg Oncol; 2021 Oct; 28(10):5495-5506. PubMed ID: 34374914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.
    Liu Y; Wang Y; Wang Y; Xie Y; Cui Y; Feng S; Yao M; Qiu B; Shen W; Chen D; Du G; Chen X; Liu Z; Li Z; Yang X; Liang C; Wu L
    EClinicalMedicine; 2022 Oct; 52():101562. PubMed ID: 35928032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
    Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
    Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The management of HER2-positive early breast cancer: Current and future therapies.
    Chen J; Colosimo M; Lim E
    Asia Pac J Clin Oncol; 2021 Sep; 17 Suppl 6():3-12. PubMed ID: 34490737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
    Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study.
    Lu H; Yan H; Liao S; Deng J; Zhang J; Yao F; Zheng H; Sun S; Zhang Y
    Transl Cancer Res; 2023 Jun; 12(6):1490-1502. PubMed ID: 37434677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: A single-institution experience.
    Joshi S; Chougle Q; Noronha J; Hawaldar R; Nair N; Vanmali V; Parmar V; Thakkar P; Chitkara G; Shet T; Badwe RA
    Indian J Cancer; 2024 Apr; 61(2):324-331. PubMed ID: 36861728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer.
    Bischoff H; Espié M; Petit T
    Curr Treat Options Oncol; 2024 Sep; 25(9):1225-1237. PubMed ID: 39153019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer.
    Martínez-Sáez O; Waks AG
    Curr Treat Options Oncol; 2023 May; 24(5):479-495. PubMed ID: 36995527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study.
    He X; Ji J; Qdaisat A; Esteva FJ; Yeung SJ
    Lancet Reg Health Am; 2024 Apr; 32():100712. PubMed ID: 38495316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer.
    Barot SV; Roesch E; Abraham J
    Expert Rev Anticancer Ther; 2022 Dec; 22(12):1289-1299. PubMed ID: 36373394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
    Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
    Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
    Spring LM; Bar Y; Isakoff SJ
    J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal treatment of early stage HER2-positive breast cancer.
    Pernas S; Barroso-Sousa R; Tolaney SM
    Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
    Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP
    Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.
    Sharma P; Connolly RM; Roussos Torres ET; Thompson A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-16. PubMed ID: 32315235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing (neo)adjuvant treatment of HER2-positive breast cancer.
    Basho RK; McArthur HL
    Ther Adv Med Oncol; 2018; 10():1758835918775697. PubMed ID: 30034547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.